Retatrutide
Also known as: LY3437943, ly3437943, triple G agonist, GIP/GLP-1/glucagon agonist, GLP-1/GIP/glucagon triple agonist
Triple GIP/GLP-1/glucagon receptor co-agonist in clinical trials for obesity and metabolic disease.
Quick Reference
Retatrutide - Research Images
PSO vial render · Scientific images from Wikipedia · Tap to enlarge
Overview
Chemical compound
Retatrutide is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist on the GLP-1, GIP, and glucagon receptors.
Mechanism of Action
Retatrutide is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist on the GLP-1, GIP, and glucagon receptors.
What is Retatrutide?
Retatrutide is an experimental triple-agonist peptide being studied by Eli Lilly. In clinical trials, it targets three hormone receptors (GLP-1, GIP, and glucagon) involved in appetite and energy balance. Researchers are watching it closely because phase 2 results showed some of the largest weight changes ever recorded in obesity trials. It is not FDA approved.
How It Works - Simply Explained
Most metabolic peptides studied so far pull one or two hormonal levers. Retatrutide pulls three at once. In research settings, it activates the GLP-1 receptor (linked to appetite signaling), the GIP receptor (linked to how the body handles nutrients), and the glucagon receptor (linked to energy expenditure). Scientists are studying whether hitting all three pathways together explains the unusually large effects seen in trials. Think of it as a three-key chord instead of a single note.
What Studies Have Found
Phase 2 trial: up to 24.2% weight change at 48 weeks
In a phase 2 trial of adults with obesity, researchers reported that participants on the highest tested dose lost an average of 24.2% of body weight after 48 weeks. For context, earlier single- and dual-pathway drugs in similar trials typically landed in the mid-teens. The trial authors noted that gastrointestinal side effects were the most common adverse events and tended to be dose-related.
Jastreboff et al., 2023, New England Journal of Medicine
Meta-analysis: retatrutide vs tirzepatide by the numbers
A 2025 network meta-analysis pooled trial data and estimated retatrutide at minus 16.34 kg (minus 23.77%) versus tirzepatide at minus 11.82 kg (minus 16.79%). The same analysis flagged a higher relative risk of adverse events for retatrutide (4.10) than for tirzepatide (2.78). The researchers cautioned that indirect comparisons are no substitute for a direct head-to-head trial.
SUN-659 network meta-analysis, 2025, Journal of the Endocrine Society
The real showdown is coming: Lilly head-to-head readout expected December 2026
Eli Lilly is running a dedicated head-to-head trial of retatrutide versus tirzepatide (trial identifier NCT06662383) enrolling about 800 participants. Results are expected in December 2026. Scientists say this will be the first true apples-to-apples comparison, and the outcome could reshape how researchers rank the newest metabolic peptides.
ClinicalTrials.gov identifier NCT06662383, trial design summaries 2024-2026
Why three receptors may beat one or two
Early mechanistic research suggests each receptor contributes something different: appetite signaling, nutrient handling, and energy burn. Preclinical studies indicated the glucagon component may add energy-expenditure effects that dual agonists lack. Researchers are still mapping exactly how the three pathways interact, which is part of what makes this compound so closely watched.
Coskun et al., 2022, Molecular Metabolism
Last updated 2026-10-06. New findings are added as published research appears.
Frequently Asked Questions
Is retatrutide FDA approved?
No. Retatrutide is an investigational compound studied in clinical trials. It has not been approved by the FDA for any indication, and published estimates have pointed to a possible approval no earlier than late 2027. Anything sold online as retatrutide is for laboratory research use only.
How is retatrutide different from tirzepatide and semaglutide?
Semaglutide targets one receptor (GLP-1), tirzepatide targets two (GLP-1 and GIP), and retatrutide targets three (GLP-1, GIP, and glucagon). Researchers are studying whether the third pathway, glucagon-driven energy expenditure, explains the larger effects seen in retatrutide trials.
What did the clinical trials find?
In the published phase 2 trial, the highest dose group averaged 24.2% weight loss at 48 weeks. A 2025 meta-analysis estimated minus 16.34 kg overall versus minus 11.82 kg for tirzepatide, while also flagging a higher rate of adverse events. A direct head-to-head trial is expected to report in December 2026.
When will we know how retatrutide compares directly to tirzepatide?
Eli Lilly is running a dedicated head-to-head trial (NCT06662383) with results expected in December 2026. Until then, all comparisons come from indirect meta-analyses, which researchers consider less reliable than a direct trial.
What side effects were reported in trials?
Published trial reports describe gastrointestinal effects such as nausea, vomiting, and diarrhea as the most common adverse events, generally dose-related. The 2025 meta-analysis estimated a higher adverse-event relative risk for retatrutide than for tirzepatide. These are trial observations, not guidance for use.
What does triple agonist mean in plain English?
It means one molecule activates three different hormone receptors instead of one. Each receptor is part of a different signaling pathway tied to appetite, nutrient handling, or energy burn. Scientists are studying whether combining all three produces effects no single pathway can achieve alone.
Can I buy retatrutide for personal use?
No. Retatrutide sold by research suppliers is for in-vitro laboratory research only. It is not for human consumption, has not been evaluated by the FDA, and is not a medicine. This page describes published research only.
What Researchers Are Saying
Community Reports - Not Medical Advice
The following is aggregated from public forums, Reddit, and research communities. These are anecdotal reports from researchers only - not verified clinical data and not a recommendation of any kind.
Retatrutide (also known as LY3437943, ly3437943) is studied within the metabolic and weight management research community. Triple GIP/GLP-1/glucagon receptor co-agonist in clinical trials for obesity and metabolic disease.
Last updated October 28, 2026
Research status: emerging. Retatrutide appears across metabolic and weight management research forums and academic literature. Researchers note this compound falls in the weight loss category.
Last updated October 28, 2026
What Do You Think of This Peptide?
Share your opinion or research experience with Retatrutide. Comments are reviewed before appearing.